Rapid AST with
MIC & SIR direct from PBC
Full Expert System on board
with dynamic algorithm
Easy to use interface
with low hands-on time
Continuous loading for optimal handling of urgent care patients
Incorporationg international guidelines & recommendations: EUCAST, CLSI & CA-SFM
LIS BI-directional with easy Bacteria
Identification integration
An overall combined CA for both GNs and GPs of 96.3%. The presented time to report data obtained by QMAC-dRASTTM in this study being of 3-8 hours for blood-culture specimens examined strongly support a further possible improvement in the workflow for handling blood stream infections.
Reporting based on MALDI-TOF MS results on susceptible/resistant pathogens, optimal targeted treatment was found respectively in 79%/63%, unnecessary broad-spectrum treatment in 16%/5%, suboptimal treatment in 4%/1%, and appropriate antibiotic treatment 100%/68%. Adding QMAC-dRAST results to the decision making raised the percentage of optimal antibiotic treatments to 98.2%
Gram Positive / Gram Negative panels for positive blood culture
GRAM POSITIVE & NEGATIVE
By eliminating requirement for sub-cultures, dRAST™ improves your lab efficiency by reducing TAT for Antibiotic Susceptibility testing
dRAST™ system does not require turbidity measurements
on dRASTTM GN panel, we feature 4 drug mixes:
-Cefotaxime
-Cefotaxime / Clavulanic acid
-Ceftazidime
-Ceftazidime / Clavulanic acid
Based on CLSI decision matrix, dRASTTM will analyze the difference of MIC within these 4 drug mixes.
dRASTTM will therefore produce an ESBL result : Negative or Positive based on MIC differences
With 8 wells on Imipenem and 8 wells on Meropenem, we have a very clear MIC result which clearly indicates if the bacteria is resistant or not to carbapenem drugs. This also applies to Pseudomonas aeruginosa and Acinetobacter baumannii
dRASTTM does not feature an AmpC flag per se but with the 3 cephalosporin drugs present on GN panel (Cefepime, Cefotaxime, Ceftazidime), dRASTTM provides a clear susceptibility information regarding any resistance towards cephalosporin drugs.
For Staphylococcus aureus, Staphylococcus lugdunensis & Staphylococcus saprophyticus, we feature Oxacillin and Cefoxitin Screen which clearly indicates the difference between MRSA & MSSA.
For other Staphylococcus species, resistance is determined on Oxacillin MIC results. Cefoxitin Screen is less susceptible for these species.
Yes. If the strain is resistant to Erythromycin, in this case, dRASTTM considers the iCLI well on GP panel (mix of Erythromycin/Clindamycin). If any growth on iCLI well, iCLI appears positive and resistance to Clindamycin is detected
With 7 wells on Vancomycin, MIC result is produced on Vancomycin providing clear indication of VRE.
With 7 wells on Teicoplanin and 7 wells on Vancomycin, MIC result is produced on dRASTTM providing clear indication of GISA presence.